A Phase 2 interventional study of Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine and Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine in Meningitis, Meningococcal Meningitis and Meningococcal Infections, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 36 sites in 2 countries. Open to participants aged 10 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-04.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Meningitis, Meningococcal by Sanofi — none open to participants now, none under way, none of them phase 3. Meningitis, Meningococcal · Sanofi.
Among the 24 studies in Meningitis, Meningococcal by Sanofi, this one is the 3rd largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2014, is one of 6 in phase 2, and was the 9th registered.
125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.
Browse Meningitis, Meningococcal studies →None of the 24 studies in Meningitis, Meningococcal by Sanofi is open now. The open studies under Meningitis, Meningococcal, anywhere →
Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 13 · Phase 4 3
First in 2006; this study’s year is marked. 1 started in 2014.
This study's enrollment of 1,715 is above the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.
Median enrollment 907 across the 23 interventional studies, 100 across the 1 observational. Of the 24 that completed or were terminated, 22 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Sanofi Pasteur, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 24 studies in Meningitis, Meningococcal by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study was to evaluate the immunogenicity and describe the safety of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine compared to the licensed vaccine MENVEO® in adolescents 10 to 17 years of age in the United States (US). This study also evaluated the immunogenicity and safety of MenACYW Conjugate vaccine when given alone compared to when given concomitantly with tetanus, diphtheria, acellular pertussis (Tdap) vaccine and human papilloma virus (HPV) vaccine.
Primary objective:
Secondary objective:
Observational objective:
Healthy adolescents were randomized and received a single dose of their assigned vaccines. They were assessed for immunogenicity at baseline (pre-vaccination) and at 30 days post-vaccination. Safety information were collected post-vaccination and throughout the entire study.
125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.
This study's enrollment of 1,715 is above the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.
Browse Meningitis, Meningococcal studies →Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
First submitted after Sanofi Pasteur became part of Sanofi.
Compared within Meningitis, Meningococcal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Meningitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MenACYW Conjugate vaccine on Day 0.
Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine
Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MENVEO® vaccine on Day 0.
Biological: Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MenACYW Conjugate vaccine, Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap), and Dose 1 of HPV Vaccine on Day 0. HPV Vaccine Dose 2 and Dose 3 were given at 2 and 6 months, respectively, after Dose 1 given on Day 0.
Biological: Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed · Biological: GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant · Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine
Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of Tdap and Dose 1 of HPV Vaccine on Day 0. HPV Vaccine Dose 2 and Dose 3 were given at 2 and 6 months, respectively, after Dose 1 given on Day 0.
Biological: Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed · Biological: GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant
0.5 milliliter (mL), Intramuscular (IM)
Also known as: MenACYW Conjugate vaccine
0.5 mL, IM
Also known as: MENVEO®
Drug page: AdacelStudies of AdacelAdacel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
0.5 mL, IM
Also known as: Adacel® (Tdap)
Drug page: Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18Studies of Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
0.5 mL, IM
Also known as: GARDASIL® (HPV)
0.5 mL, Intramuscular (IM)
Also known as: MenACYW Conjugate vaccine
Drug page: AdacelStudies of AdacelAdacel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
0.5 mL, IM
Also known as: Adacel® (Tdap)
Drug page: Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18Studies of Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
0.5 mL, IM
Also known as: GARDASIL® (HPV)
Percentage of Participants Achieving Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or MENVEO® Vaccine
Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers greater than or equal to (\>=) 1:8 for participants with pre-vaccination hSBA titers less than (\<) 1:8 or at least a 4-fold increase in hSBA titers from pre- to post vaccination for participants with pre-vaccination hSBA titers \>= 1:8. Data for this outcome measure was not planned to be collected and analyzed for Group 4:Tdap+HPV.
Time frame: Day 30 (post-vaccination)
Percentage of Participants Achieving hSBA Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or MenACYW Conjugate Vaccine Given With Tdap and HPV Vaccines
Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \>= 1:8 for participants with pre-vaccination hSBA titers \< 1:8 or at least a 4-fold increase in hSBA titers from pre- to post vaccination for participants with pre-vaccination hSBA titers \>= 1:8.
Time frame: Day 30 (post-vaccination on Day 0)
Geometric Mean Concentrations (GMCs) of PT, FHA, PRN, and FIM Antibodies Following Vaccination With Either MenACYW Conjugate Vaccine Given With Tdap and HPV Vaccines or Tdap and HPV Vaccines
Anti-Pertussis toxoid (PT), Filamentous hemagglutinin (FHA), Pertactin (PRN), and Fimbriae types 2 and 3 (FIM) antibodies were measured by enzyme-linked immunosorbent assay (ELISA).
Time frame: Day 30 (post-vaccination on Day 0)
Percentage of Participants Achieving Anti-Tetanus and Anti-Diphtheria Concentrations >= 1.0 International Unit (IU)/mL Following Vaccination With Either MenACYW Conjugate Vaccine Given With Tdap and HPV Vaccines or Tdap and HPV Vaccines
Anti-Diphtheria antibodies were measured by a toxin neutralization test. Anti-Tetanus antibodies were measured by ELISA.
Time frame: Day 30 (post-vaccination on Day 0)
Percentage of Participants Achieving Seroconversion for Anti-HPV6, HPV11, HPV16, and HPV18 Antibodies Following Vaccination With Either MenACYW Conjugate Vaccine Given With Tdap and HPV Vaccines or Tdap and HPV Vaccines
Anti-HPV 6, 11, 16, and 18 antibodies were measured using a competitive Luminex immunoassay. Seroconversion was defined as changing serostatus from seronegative to seropositive. Cutoff values for HPV seropositivity were \>= 20 milli-Merck units per milliliter (mMU/mL) for types 6 and 16, \>= 16 mMU/mL for type 11, and \>= 24mMU/mL for type 18.
Time frame: Day 210 (post-vaccination on Day 0)
Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Vaccination With MenACYW Conjugate Vaccine or MENVEO® Vaccine at Day 0: Group 1 and Group 2
A Solicited Reaction (SR) was an Adverse Event (AE) that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions included: Pain, Erythema, and Swelling.
Time frame: Within 7 days after vaccines injections at Day 0
Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Vaccination With MenACYW Conjugate Vaccine Given With Tdap and HPV Vaccines at Day 0: Group 3
A SR was an AE that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions included: Pain, Erythema, and Swelling.
Time frame: Within 7 days after vaccines injections at Day 0
Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Vaccination With Tdap and HPV Vaccines at Day 0: Group 4
A SR was an AE that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions included: Pain, Erythema, and Swelling.
Time frame: Within 7 days after vaccines injections at Day 0
Study participants were enrolled in 40 centers in the Unites States (US) from 22 July 2014 to 25 February 2015.
| Milestone | Group 1: MenACYW Conjugate Vaccine | Group 2: MENVEO® Vaccine | Group 3: MenACYW Conjugate Vaccine+Tdap+HPV | Group 4: Tdap+HPV |
|---|---|---|---|---|
| Started | 505 | 507 | 403 | 300 |
| Safety analysis set (safas) | 503 | 501 | 392 | 296 |
| Completed | 495 | 500 | 376 | 270 |
| Not completed | 10 | 7 | 27 | 30 |
| Withdrew: Protocol violation | 3 | 3 | 6 | 7 |
| Withdrew: Withdrawal by subject | 5 | 3 | 12 | 13 |
| Withdrew: Lost to follow-up | 2 | 1 | 9 | 10 |
Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers greater than or equal to (\>=) 1:8 for participants with pre-vaccination hSBA titers less than (\<) 1:8 or at least a 4-fold increase in hSBA titers from pre- to post vaccination for participants with pre-vaccination hSBA titers \>= 1:8. Data for this outcome measure was not planned to be collected and analyzed for Group 4:Tdap+HPV.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: MENVEO® Vaccine |
|---|---|---|
| Serogroup A | 75.6 (71.4 to 79.4) | 66.4 (61.9 to 70.7) |
| Serogroup C | 97.2 (95.2 to 98.5) | 72.6 (68.3 to 76.6) |
| Serogroup Y | 97.0 (95.0 to 98.3) | 80.8 (76.9 to 84.3) |
| Serogroup W | 86.2 (82.7 to 89.2) | 66.6 (62.1 to 70.9) |
Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \>= 1:8 for participants with pre-vaccination hSBA titers \< 1:8 or at least a 4-fold increase in hSBA titers from pre- to post vaccination for participants with pre-vaccination hSBA titers \>= 1:8.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 3: MenACYW Conjugate Vaccine+Tdap+HPV |
|---|---|---|
| Serogroup A | 75.6 | 80.6 |
| Serogroup C | 97.2 | 97.2 |
| Serogroup Y | 97.0 | 95.6 |
| Serogroup W | 86.2 | 83.9 |
Anti-Pertussis toxoid (PT), Filamentous hemagglutinin (FHA), Pertactin (PRN), and Fimbriae types 2 and 3 (FIM) antibodies were measured by enzyme-linked immunosorbent assay (ELISA).
| ELISA units (EU)/mL | Group 3: MenACYW Conjugate Vaccine+Tdap+HPV | Group 4: Tdap+HPV |
|---|---|---|
| Anti-Pertussis toxoid (PT) | 37.5 (33.8 to 41.7) | 44.4 (39.5 to 49.9) |
| Filamentous hemagglutinin (FHA) | 180 (168 to 194) | 242 (218 to 268) |
| Pertactin (PRN) | 200 (177 to 225) | 265 (231 to 304) |
| Fimbriae types 2 and 3 (FIM) | 339 (285 to 403) | 499 (414 to 601) |
Anti-Diphtheria antibodies were measured by a toxin neutralization test. Anti-Tetanus antibodies were measured by ELISA.
| percentage of participants | Group 3: MenACYW Conjugate Vaccine+Tdap+HPV | Group 4: Tdap+HPV |
|---|---|---|
| Diphtheria | 97.8 (95.7 to 99.0) | 98.9 (96.7 to 99.8) |
| Tetanus | 99.7 (98.5 to 100.0) | 99.6 (97.9 to 100.0) |
Anti-HPV 6, 11, 16, and 18 antibodies were measured using a competitive Luminex immunoassay. Seroconversion was defined as changing serostatus from seronegative to seropositive. Cutoff values for HPV seropositivity were \>= 20 milli-Merck units per milliliter (mMU/mL) for types 6 and 16, \>= 16 mMU/mL for type 11, and \>= 24mMU/mL for type 18.
| percentage of participants | Group 3: MenACYW Conjugate Vaccine+Tdap+HPV | Group 4: Tdap+HPV |
|---|---|---|
| HPV Type 6 | 97.5 (94.7 to 99.1) | 95.7 (91.4 to 98.3) |
| HPV Type 11 | 99.6 (97.7 to 100.0) | 98.8 (95.7 to 99.9) |
| HPV Type 16 | 99.2 (97.0 to 99.9) | 98.8 (95.7 to 99.9) |
| HPV Type 18 | 99.2 (97.0 to 99.9) | 98.8 (95.7 to 99.9) |
A Solicited Reaction (SR) was an Adverse Event (AE) that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions included: Pain, Erythema, and Swelling.
| Participants | Group 1: MenACYW Conjugate Vaccine | Group 2: MENVEO® Vaccine |
|---|---|---|
| Pain | 224 | 209 |
| Erythema | 25 | 37 |
| Swelling | 27 | 32 |
A SR was an AE that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions included: Pain, Erythema, and Swelling.
| Participants | Group 3: MenACYW Conjugate Vaccine+Tdap+HPV |
|---|---|
| MenACYW site: Pain | 183 |
| MenACYW site: Erythema | 15 |
| MenACYW site: Swelling | 17 |
| Tdap site: Pain | 286 |
| Tdap site: Erythema | 28 |
| Tdap site: Swelling | 24 |
| HPV site: Pain | 288 |
| HPV site: Erythema | 31 |
| HPV site: Swelling | 26 |
A SR was an AE that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions included: Pain, Erythema, and Swelling.
| Participants | Group 4: Tdap+HPV |
|---|---|
| Tdap site: Pain | 211 |
| Tdap site: Erythema | 14 |
| Tdap site: Swelling | 20 |
| HPV site: Pain | 201 |
| HPV site: Erythema | 16 |
| HPV site: Swelling | 23 |
Collected over Adverse event (AE) data were collected from Day 0 (post-vaccination) up to 30 days after last vaccination. SR data were collected within 7 days after any vaccination. Serious adverse events (SAEs) data were collected throughout the study (up to 180 days after vaccination for Group 1 and 2, and up to 210 days after vaccination on Day 0 for Group 3 and 4).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: MenACYW Conjugate Vaccine | 0/503 (0%) | 4/503 (0.8%) | 331/503 (65.8%) |
| Group 2: MENVEO® Vaccine | 0/501 (0%) | 4/501 (0.8%) | 337/501 (67.3%) |
| Group 3: MenACYW Conjugate Vaccine+Tdap+HPV | 0/392 (0%) | 4/392 (1%) | 348/392 (88.8%) |
| Group 4: Tdap+HPV | 0/296 (0%) | 4/296 (1.4%) | 263/296 (88.9%) |
| Event | Group 1: MenACYW Conjugate Vaccine | Group 2: MENVEO® Vaccine | Group 3: MenACYW Conjugate Vaccine+Tdap+HPV | Group 4: Tdap+HPV |
|---|---|---|---|---|
| AppendicitisInfections and infestations | 0/503 | 1/501 | 0/392 | 2/296 |
| Staphylococcal Scalded Skin SyndromeInfections and infestations | 0/503 | 0/501 | 0/392 | 1/296 |
| Suicidal IdeationPsychiatric disorders | 0/503 | 0/501 | 1/392 | 1/296 |
| HypothyroidismEndocrine disorders | 0/503 | 0/501 | 1/392 | 0/296 |
| ConvulsionNervous system disorders | 1/503 | 0/501 | 1/392 | 0/296 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/503 | 0/501 | 1/392 | 0/296 |
| Abnormal BehaviourPsychiatric disorders | 0/503 | 1/501 | 0/392 | 0/296 |
| Major DepressionPsychiatric disorders | 0/503 | 1/501 | 0/392 | 0/296 |
| Erythema MultiformeSkin and subcutaneous tissue disorders | 0/503 | 1/501 | 0/392 | 0/296 |
| FaecalomaGastrointestinal disorders | 1/503 | 0/501 | 0/392 | 0/296 |
| Event | Group 1: MenACYW Conjugate Vaccine | Group 2: MENVEO® Vaccine | Group 3: MenACYW Conjugate Vaccine+Tdap+HPV | Group 4: Tdap+HPV |
|---|---|---|---|---|
| Injection Site PainGeneral disorders | 224/503 | 209/501 | 327/392 | 234/296 |
| MyalgiaMusculoskeletal and connective tissue disorders | 175/503 | 173/501 | 239/392 | 161/296 |
| HeadacheNervous system disorders | 155/503 | 159/501 | 137/392 | 87/296 |
| MalaiseGeneral disorders | 130/503 | 131/501 | 113/392 | 81/296 |
| Injection Site ErythemaGeneral disorders | 25/503 | 37/501 | 44/392 | 24/296 |
| Injection Site SwellingGeneral disorders | 27/503 | 32/501 | 42/392 | 32/296 |
| Upper Respiratory Tract InfectionInfections and infestations | 24/503 | 30/501 | 27/392 | 12/296 |
| PharyngitisInfections and infestations | 15/503 | 32/501 | 22/392 | 14/296 |
Analysis was performed on all randomized participants.
| Age, Continuous(years) | Group 1: MenACYW Conjugate Vaccine | Group 2: MENVEO® Vaccine | Group 3: MenACYW Conjugate Vaccine+Tdap+HPV | Group 4: Tdap+HPV | Total |
|---|---|---|---|---|---|
| Mean | 11.4 ± 1.39 | 11.4 ± 1.39 | 11.3 ± 1.06 | 11.4 ± 1.41 | 11.4 ± 1.32 |
| Sex: Female, Male(Participants) | Group 1: MenACYW Conjugate Vaccine | Group 2: MENVEO® Vaccine | Group 3: MenACYW Conjugate Vaccine+Tdap+HPV | Group 4: Tdap+HPV | Total |
|---|---|---|---|---|---|
| Female | 259 | 232 | 197 | 144 | 832 |
| Male | 246 | 275 | 206 | 156 | 883 |
| Race (NIH/OMB)(Participants) | Group 1: MenACYW Conjugate Vaccine | Group 2: MENVEO® Vaccine | Group 3: MenACYW Conjugate Vaccine+Tdap+HPV | Group 4: Tdap+HPV | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 3 | 0 | 4 | 1 | 8 |
| Asian | 3 | 3 | 1 | 1 | 8 |
| Native Hawaiian or Other Pacific Islander | 1 | 2 | 2 | 5 | 10 |
| Black or African American | 30 | 22 | 15 | 18 | 85 |
| White | 442 | 456 | 361 | 261 | 1520 |
| More than one race | 26 | 24 | 20 | 12 | 82 |
| Unknown or Not Reported | 0 | 0 | 0 | 2 | 2 |
| Region of Enrollment(Participants) | Group 1: MenACYW Conjugate Vaccine | Group 2: MENVEO® Vaccine | Group 3: MenACYW Conjugate Vaccine+Tdap+HPV | Group 4: Tdap+HPV | Total |
|---|---|---|---|---|---|
| United States | 505 | 507 | 403 | 300 | 1715 |
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Jul 2014 to primary completion in Oct 2015, 14 months.
Results were first posted in Jun 2020, 4 years 8 months after primary completion. A results delay was requested in Sep 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Adacel · Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
Sanofi Pasteur, a Sanofi Company →